SCHEMBL30600499

SCHEMBL30600499

CCc1ccccc1C(=O)n1nc(N)c2ccc(C3CC3)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.40
▸ TP53 P04637 6/20 0.40
▸ HTT P42858 5/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ PKM P14618 1/20 0.40
▸ HCRTR2 O43614 6/20 0.38
▸ HCRTR1 O43613 3/20 0.38
▸ TTR P02766 1/20 0.38
▸ ELANE P08246 1/20 0.37
▸ SRC P12931 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ DUSP3 P51452 1/20 0.33
▸ PTPN5 P54829 1/20 0.33
▸ PTPN11 Q06124 1/20 0.33
▸ CTDSP1 Q9GZU7 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ LMNA P02545 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26675343 1.00 MAPT (0.40) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675338 0.87 ENPP3 (0.42) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675432 0.84 ALOX15 (0.48) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675328 0.83 HCRTR1 (0.38) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL30600526 0.83 HCRTR1 (0.38) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL30600511 0.83 ENPP3 (0.41) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675330 0.83 ENPP3 (0.41) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675349 0.83 ENPP3 (0.41) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL30600507 0.82 ELANE (0.46) MAPTTP53HTTSMN1; SMN2PKM
SCHEMBL26675320 0.82 ELANE (0.46) MAPTTP53HTTSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US claimed
CN-116867782-A Pyrazole amide derivative 豪夫迈·罗氏有限公司 2023-10-10 — — CN claimed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
CN-116867782-A Pyrazole amide derivative 豪夫迈·罗氏有限公司 2023-10-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES P2RY1, P2RX1, P2RX5 MAPT 3058/4885TP53 3001/4885HTT 4269/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B MAPT 2409/4885TP53 4794/4885HTT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback